Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Castro

Showing results (161-170 of 194) with videos related to

Pageof 20
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancerVincenza Conteduca, Elena Castro, Daniel Wetterskog, et al.
JAMA Oncology|July 25, 2024
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A ReviewHeather H Cheng, Jeffrey W Shevach, Elena Castro, et al.
Translational Psychiatry|November 20, 2019
Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychoticsFulgencio Ruso-Julve, Ana Pombero, Fuencisla Pilar-Cuéllar, et al.
British Journal of Cancer|August 23, 2018
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)Nuria Romero-Laorden, Rebeca Lozano, Anuradha Jayaram, et al.
BJU International|January 17, 2013
Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohortChee L Goh, Edward J Saunders, Daniel A Leongamornlert, et al.
European Urology|December 3, 2014
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate CancerElena Castro, Chee Goh, Daniel Leongamornlert, et al.
European Urology Oncology|July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative AnalysisPasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2021
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancerRebeca Lozano, Daniela C Salles, Shahneen Sandhu, et al.
Science Advances|October 2, 2024
SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancerAntonio J Montero-Hidalgo, Juan M Jiménez-Vacas, Enrique Gómez-Gómez, et al.
European Urology|February 19, 2019
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate CancerVincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, et al.
Pageof 20

Showing results (161-170 of 194) with videos related to

Sort By:
Pageof 20
European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancerVincenza Conteduca, Elena Castro, Daniel Wetterskog, et al.
JAMA Oncology|July 25, 2024
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A ReviewHeather H Cheng, Jeffrey W Shevach, Elena Castro, et al.
Translational Psychiatry|November 20, 2019
Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychoticsFulgencio Ruso-Julve, Ana Pombero, Fuencisla Pilar-Cuéllar, et al.
British Journal of Cancer|August 23, 2018
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)Nuria Romero-Laorden, Rebeca Lozano, Anuradha Jayaram, et al.
BJU International|January 17, 2013
Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohortChee L Goh, Edward J Saunders, Daniel A Leongamornlert, et al.
European Urology|December 3, 2014
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate CancerElena Castro, Chee Goh, Daniel Leongamornlert, et al.
European Urology Oncology|July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative AnalysisPasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2021
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancerRebeca Lozano, Daniela C Salles, Shahneen Sandhu, et al.
Science Advances|October 2, 2024
SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancerAntonio J Montero-Hidalgo, Juan M Jiménez-Vacas, Enrique Gómez-Gómez, et al.
European Urology|February 19, 2019
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate CancerVincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, et al.
Pageof 20